Enanta Pharmaceuticals | ENTA - Des Atouts





Des Atouts Changement Date
AbbVie USD 147.68B 12.57B 2026-09
Amgen USD 96.05B 409M 2026-09
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
AstraZeneca USD 119.92B 4.09B 2026-09
BioCryst Pharmaceuticals USD 591.07M 33.22M 2026-09
Biogen USD 32.05B 32.5M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 51.41B 2.05B 2026-09
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
Halozyme Therapeutics USD 3.47B 895.94M 2026-09
Heron Therapeutics USD 252.26M 6.05M 2026-06
Immunic USD 189.74M 165.69M 2026-03
Incyte USD 7.29B 585.39M 2026-09
Insmed USD 2.23B 123.49M 2026-09
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
J&J USD 197.42B 3.64B 2026-09
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Ligand Pharmaceuticals USD 2.24B 51.59M 2026-09
Merck USD 132.77B 2.97B 2026-09
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
Novartis USD 117.15B 4.88B 2026-09
Novavax USD 888M 67.57M 2026-09
Pfizer USD 204.54B 3.41B 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sarepta Therapeutics USD 3.17B 22.45M 2026-09
Vertex Pharmaceuticals USD 32.74B 5.31B 2026-09